Multiple Sclerosis

The consultant neurologist at Torbay and Southern Devon Healthcare NHS Foundation Trust discussed how combining advanced therapies with lifestyle modifications can improve outcomes and slow disease progression in patients with multiple sclerosis. [WATCH TIME: 4 minutes]

The assistant professor of neurology at UCSF Weill Institute for Neurosciences talked about a study that explored the use of commercial wearable devices to monitor and manage bladder dysfunction in multiple sclerosis. [WATCH TIME: 6 minutes]

The head of the MS Center at Methodist Hospitals discussed the need for inclusive and affirming healthcare practices for patients with multiple sclerosis who identify as LGBTQ+.

The professor of neurology at Stony Brook Medicine talked about the diagnosis of primary progressive multiple sclerosis, a unique MS phenotype characterized by a gradual deterioration without initial attack. [WATCH TIME: 5 minutes]

The assistant professor at Hunter College emphasized the important role of localization and accurately identifying the origin of neurological symptoms when diagnosing and managing multiple sclerosis. [WATCH TIME: 7 minutes]

The associate vice president of research at National MS Society talked about proactive and early referral to rehabilitation services to effectively manage multiple sclerosis symptoms from the outset. [WATCH TIME: 4 minutes]

The assistant professor of neurology in the Perelman School of Medicine at University of Pennsylvania talked about her presentation at CMSC 2024 on the complex interactions of immune cells in multiple sclerosis. [WATCH TIME: 6 minutes]

The professor of psychiatry at the University of Toronto discussed the various medications for multiple sclerosis fatigue that have been tested but ultimately fail to outperform placebo. [WATCH TIME: 4 minutes]

A recent survey reported a high prevalence of burnout among physicians treating patients with multiple sclerosis, highlighting long work hours as one of the key factors.

Within a subgroup of those older than 50 years, most patients who switched to cladribine were relapse free at follow-up, with no new safety signals observed.

The clinical research director of the UCSF Multiple Sclerosis Center talked about results from clinical trials assessing BTK inhibitors in relapsing multiple sclerosis and the ongoing research to explore more effective treatments. [WATCH TIME: 5 minutes]

CMSC Kurtzke Lecturer Darin Okuda, MD, demonstrates innovative ways to rethink MRI use in MS.

In a new analysis of the CHIMES trial, ocrelizumab displayed a trend toward improved work productivity among minority patients with relapsing multiple sclerosis.

The clinical research director of the UCSF Multiple Sclerosis Center discussed the early-onset progression in multiple sclerosis and emphasized the need for targeted therapies in this patient population. [WATCH TIME: 6 minutes]

Nearly half of patients on diphenhydramine, dexamethasone, and famotidine experienced moderate to severe decreased alertness vs only 12.9% of those on cetirizine, dexamethasone, and famotidine.

Overall, the results mirrored previous reports demonstrating that patients on ocrelizumab before or during pregnancy did not have elevated risk of adverse pregnancy and infant outcomes.

The 38th CMSC Annual Meeting is set to be held May 29-June 1, 2024, in Nashville, Tennessee. The International Journal of MS Care has published the abstracts.

The International Journal of MS Care publishes the abstracts for the CMSC Annual Meeting, which is set to be held May 29-June 1, 2024, in Nashville, Tennessee.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the need for biomarkers that can help guide the optimal dosing for the use of anti-CD20 therapies in a precision fashion.

The Consortium of Multiple Sclerosis Centers' 38th Annual Meeting will be held Wednesday, May 29, through Saturday, June 1, 2024 at the Music City Center, in Nashville, Tennessee.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the utility of real-world data, particularly when it comes to understanding subtle differences between agents from both a safety and efficacy perspective.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss emerging the practical implications of long-term data for anti-CD20 agents.

The director of the PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital talked about nasal administration of foralumab that shows promise in treating patients with non-active secondary progressive MS. [WATCH TIME: 5 minutes]

Ahmed Obeidat, MD, PhD, and Riley Bove, MD, review strategies for how to make drug classes and the risks-benefits profiles of individual agents accessible to patients.